Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)

NCT06694701 is registered in ClinicalTrials.gov with Hellenic Institute for the Study of Sepsis as lead sponsor.

NCT NCT06694701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06694701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)
Lead sponsor
Hellenic Institute for the Study of Sepsis
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 22, 2025
Completion date
November 30, 2026
Enrollment
75 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis